Ana M. Martinez

Madrid, MD 28040, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 128 publications

Screening of candidate antiparasitic drugs against Sparicotyle chrysophrii: A phenotypic drug discovery approach.

Screening of candidate antiparasitic drugs against Sparicotyle chrysophrii: A phenotypic drug discovery approach.

Journal: Veterinary parasitology

Published: June 18, 2026

Selective Brain-Penetrant TTBK1 Inhibitors Modulate TDP-43 Pathology and Rescue Cognitive Deficits in a Mouse Model of TDP-43 Proteinopathy.

Selective Brain-Penetrant TTBK1 Inhibitors Modulate TDP-43 Pathology and Rescue Cognitive Deficits in a Mouse Model of TDP-43 Proteinopathy.

Journal: Journal of medicinal chemistry

Published: June 14, 2026

Design, synthesis, and pharmacological evaluation of thiazolo[5,4-d]pyrimidines hybridized with lipoic acid or catechol. Novel A2A adenosine receptor antagonists in neuroinflammatory diseases.

Design, synthesis, and pharmacological evaluation of thiazolo[5,4-d]pyrimidines hybridized with lipoic acid or catechol. Novel A2A adenosine receptor antagonists in neuroinflammatory diseases.

Journal: Bioorganic chemistry

Published: May 15, 2026

Innovative therapies under clinical development for ALS treatment: small molecules.

Innovative therapies under clinical development for ALS treatment: small molecules.

Journal: Expert opinion on investigational drugs

Published: April 28, 2026

Nanotechnology-based encapsulation of neflamapimod: A new therapeutic strategy for lewy body dementia.

Nanotechnology-based encapsulation of neflamapimod: A new therapeutic strategy for lewy body dementia.

Journal: Colloids and surfaces. B, Biointerfaces

Published: March 18, 2026

Novel Xanthene Derivatives for Neuroprotection in Alzheimer's Disease-Synthesis and Biological Assessment.

Novel Xanthene Derivatives for Neuroprotection in Alzheimer's Disease-Synthesis and Biological Assessment.

Journal: ChemMedChem

Published: March 16, 2026

Brain Permeable SGK1 Inhibitors: A Promising Therapeutic Strategy for Neurodegenerative Diseases.

Brain Permeable SGK1 Inhibitors: A Promising Therapeutic Strategy for Neurodegenerative Diseases.

Journal: Journal of medicinal chemistry

Published: March 16, 2026

Identification of Potential Multitarget Directed Ligands for Alzheimer's Disease by Coupling Virtual Screening and Experimental Validation.

Identification of Potential Multitarget Directed Ligands for Alzheimer's Disease by Coupling Virtual Screening and Experimental Validation.

Journal: Journal of chemical information and modeling

Published: February 23, 2026

Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathy.

Assessment of the therapeutic effect of IGS2.7, a CK1δ protein kinase inhibitor, in combination with riluzole for the treatment of ALS-associated TDP-43 proteinopathy.

Journal: Neuropharmacology

Published: October 04, 2025

Design, Synthesis and Biological Evaluation of Chromeno[3,4-b]xanthones as Multifunctional Agents for Alzheimer's Disease.

Design, Synthesis and Biological Evaluation of Chromeno[3,4-b]xanthones as Multifunctional Agents for Alzheimer's Disease.

Journal: ACS chemical neuroscience

Published: August 06, 2025

Screening Natural Phenolic Compounds for Blood-Brain Barrier Permeability, Alongside GSK-3β, CK-1δ, and AChE Inhibition, for the Treatment of Alzheimer's Disease.

Screening Natural Phenolic Compounds for Blood-Brain Barrier Permeability, Alongside GSK-3β, CK-1δ, and AChE Inhibition, for the Treatment of Alzheimer's Disease.

Journal: Drug development research

Published: May 02, 2025

Structure-Based Discovery Targeting GSK-3α Reveals Potent Nanomolar Selective 4-Phenyl-1H-benzofuro[3,2-b]pyrazolo[4,3-e]pyridine Inhibitor with Promising Glioblastoma and CNS-Active Potential in Cellular Models.

Structure-Based Discovery Targeting GSK-3α Reveals Potent Nanomolar Selective 4-Phenyl-1H-benzofuro[3,2-b]pyrazolo[4,3-e]pyridine Inhibitor with Promising Glioblastoma and CNS-Active Potential in Cellular Models.

Journal: Journal of medicinal chemistry

Published: April 08, 2025

Showing 1-12 of 128

Last Updated: 09/26/2026